John Woolcott

2.7k total citations · 1 hit paper
73 papers, 2.0k citations indexed

About

John Woolcott is a scholar working on Rheumatology, Genetics and Immunology. According to data from OpenAlex, John Woolcott has authored 73 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Rheumatology, 26 papers in Genetics and 17 papers in Immunology. Recurrent topics in John Woolcott's work include Inflammatory Bowel Disease (26 papers), Rheumatoid Arthritis Research and Therapies (25 papers) and Autoimmune and Inflammatory Disorders Research (14 papers). John Woolcott is often cited by papers focused on Inflammatory Bowel Disease (26 papers), Rheumatoid Arthritis Research and Therapies (25 papers) and Autoimmune and Inflammatory Disorders Research (14 papers). John Woolcott collaborates with scholars based in United States, Canada and United Kingdom. John Woolcott's co-authors include Aslam H. Anis, Carlo A. Marra, John M. Esdaile, Robert Offer, Kam Shojania, John Brazier, Jacek A. Kopec, Lara Fallon, Daphne Guh and Philip J. Mease and has published in prestigious journals such as Gastroenterology, Social Science & Medicine and The American Journal of Cardiology.

In The Last Decade

John Woolcott

62 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Meta-analysis of the Impact of 9 Medication Classes on Falls in Elderly Persons

2009 909 citations John Woolcott profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Woolcott United States	17	375	372	368	354	316	73	2.0k
Janne Petersen Denmark	29	148 0.4×	163 0.4×	98 0.3×	488 1.4×	265 0.8×	138	3.1k
Ramón Pujol Spain	24	147 0.4×	101 0.3×	103 0.3×	269 0.8×	135 0.4×	84	1.8k
Kenneth Brummel‐Smith United States	21	100 0.3×	208 0.6×	77 0.2×	344 1.0×	273 0.9×	52	2.4k
Tamara B. Harris United States	17	132 0.4×	57 0.2×	115 0.3×	1.1k 3.0×	414 1.3×	18	4.1k
Damien Jolly France	33	251 0.7×	448 1.2×	30 0.1×	551 1.6×	649 2.1×	149	3.2k
Gülistan Bahat Türkiye	26	91 0.2×	96 0.3×	66 0.2×	887 2.5×	303 1.0×	129	2.4k
Christine T. Cigolle United States	19	46 0.1×	422 1.1×	112 0.3×	631 1.8×	185 0.6×	41	1.8k
Maria Chiara Corti Italy	24	213 0.6×	174 0.5×	32 0.1×	194 0.5×	70 0.2×	64	1.8k
Carsten Hendriksen Denmark	26	58 0.2×	210 0.6×	194 0.5×	427 1.2×	312 1.0×	97	2.7k
Éléna Paillaud France	31	64 0.2×	390 1.0×	69 0.2×	1.6k 4.5×	180 0.6×	178	3.6k

Countries citing papers authored by John Woolcott

Since Specialization

Citations

This map shows the geographic impact of John Woolcott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Woolcott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Woolcott more than expected).

Fields of papers citing papers by John Woolcott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Woolcott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Woolcott. The network helps show where John Woolcott may publish in the future.

Co-authorship network of co-authors of John Woolcott

This figure shows the co-authorship network connecting the top 25 collaborators of John Woolcott. A scholar is included among the top collaborators of John Woolcott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Woolcott. John Woolcott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sands, Bruce E., Marla C. Dubinsky, Paulo Gustavo Kotze, et al.. (2025). Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 31(10). 2681–2692.

Feagan, B G, Maia Kayal, Stefan Schreiber, et al.. (2025). P1183 Multivariable analysis of baseline variables associated with efficacy outcomes in the ELEVATE UC clinical programme. Journal of Crohn s and Colitis. 19(Supplement_1). i2149–i2150.

Charles‐Schoeman, Christina, Roy Fleischmann, Eduardo Mysler, et al.. (2024). Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients. Arthritis & Rheumatology. 76(8). 1218–1229. 13 indexed citations

Jairath, Vipul, David T. Rubin, Bram Verstockt, et al.. (2024). The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program. Inflammatory Bowel Diseases. 31(4). 923–934. 2 indexed citations

Vermeire, Séverine, Bruce E. Sands, Laurent Peyrin‐Biroulet, et al.. (2024). Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. Journal of Crohn s and Colitis. 18(11). 1780–1794. 5 indexed citations

Sands, Bruce E., Yvette Leung, David T. Rubin, et al.. (2024). Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program. Journal of Crohn s and Colitis. 19(3). 3 indexed citations

Siegmund, Britta, Catherine M. Crosby, Séverine Vermeire, et al.. (2024). S1137 The Impact of Etrasimod on the Transcriptome in Colon Biopsies Using RNA-Seq: Data from ELEVATE UC 52 and ELEVATE UC 12 Phase 3 Clinical Trials. The American Journal of Gastroenterology. 119(10S). S808–S808.

Lichtenstein, Gary R., Jessica R. Allegretti, Edward V. Loftus, et al.. (2024). P705 Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme. Journal of Crohn s and Colitis. 18(Supplement_1). i1320–i1322.

Vermeire, Séverine, Laurent Peyrin‐Biroulet, Julián Panés, et al.. (2023). P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials. Journal of Crohn s and Colitis. 17(Supplement_1). i619–i620. 9 indexed citations

10.

Rubin, David T., Joana Torres, Iris Dotan, et al.. (2023). An Insight into Patients’ Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts. Inflammatory Bowel Diseases. 30(10). 1748–1758. 4 indexed citations

11.

Regueiro, Miguel, Séverine Vermeire, David T. Rubin, et al.. (2023). S1072 Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program. The American Journal of Gastroenterology. 118(10S). S816–S817. 1 indexed citations

12.

Vermeire, Séverine, David T. Rubin, Laurent Peyrin‐Biroulet, et al.. (2023). S905 Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program. The American Journal of Gastroenterology. 118(10S). S675–S675.

13.

Panaccione, Remo, María T. Abreu, Irina Lazariciu, et al.. (2022). Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open. Alimentary Pharmacology & Therapeutics. 55(12). 1534–1544. 5 indexed citations

14.

Winthrop, Kevin, Arne Yndestad, Dan Henrohn, et al.. (2022). Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatology and Therapy. 10(2). 357–373. 3 indexed citations

15.

Taylor, Peter C., Neil Betteridge, T. Michelle Brown, et al.. (2020). <p>Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making</p>. Patient Preference and Adherence. Volume 14. 119–131. 15 indexed citations

16.

Dikranian, Ara, Valderílio Feijó Azevedo, Louis Bessette, et al.. (2018). FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY. JCR Journal of Clinical Rheumatology. 25. 1 indexed citations

17.

Rahme, Elham, et al.. (2013). Mortality and Readmission Rates After Hospitalization for Upper and Lower Gastrointestinal Events in Quebec, Canada. Journal of Clinical Gastroenterology. 47(7). 586–592. 9 indexed citations

18.

Woolcott, John, Maureen C. Ashe, William C. Miller, Peilin Shi, & Carlo A. Marra. (2009). Does physical activity reduce seniors' need for healthcare?: a study of 24 281 Canadians. British Journal of Sports Medicine. 44(12). 902–904. 42 indexed citations

19.

Anis, Aslam H., Daphne Guh, & John Woolcott. (2003). Lowering Generic Drug Prices. Medical Care. 41(1). 135–141. 29 indexed citations

20.

Munakata, Julie, John Woolcott, Aslam H. Anis, et al.. (2003). Design of a Prospective Economic Evaluation for a Tri-National Clinical Trial in HIV Patients (OPTIMA). Controlled Clinical Trials. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact